Kidneys, hearts, hormones and immunomodulators: Integrated understandings

Blood Purification

Volumn 24, Issue 1, 2006, Pages 46-50

  Levin, Adeera ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiovascular disease; Chronic kidney disease; Renin angiotensin system

Indexed keywords

ALDOSTERONE; CHEMOKINE; CYTOKINE; ERYTHROPOIETIN; HORMONE; IMMUNOMODULATING AGENT; VITAMIN D;

BIOLOGY; CARDIOVASCULAR DISEASE; CELL DAMAGE; ENDOCRINE FUNCTION; ENDOTHELIUM CELL; GLOMERULUS FILTRATION RATE; HEART; HUMAN; INFLAMMATION; KIDNEY; KIDNEY INJURY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HORMONES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; KIDNEY; KIDNEY FAILURE, CHRONIC; MYOCARDIUM;

EID: 29244488265     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089436     Document Type: Review

References (41)

1. Weiner DE, Tighiouart H, Stark PC, et al: Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206.
2. Weiner DE, Tighiouart H, Amin MG, et al: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-1315.
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
4. Clase CM, Garg AX, Kiberd BA: Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002;13:1338-1349.
5. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
6. Coresh J, Wei GL, McQuillan G, et al: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001;161:1207-1216.
7. Longenecker JC, Coresh J, Powe NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002;13:1918-1927.
8. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-510.
9. Nickolas TL, Frisch GD, Opotowsky AR, Arons R, Radhakrishnan J: Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 2004;44:185-197.
10. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
11. Zoccali C, Benedetto FA, Mallamaci F, et al: Inflammation is associated with carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 2000;18:1207-1213.
12. Zoccali C, Mallamaci F, Tripepi G: Atherosclerosis in dialysis patients: does Chlamydia pneumoniae infection contribute to cardiovascular damage? Nephrol Dial Transplant 2002;17(suppl 8):25-28; discussion 40.
13. Stenvinkel P: Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr 2003;13:144-148.
14. Blacher J, Asmar R, Djane S, London GM, Safar ME: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999;33:1111-1117.
15. Davies M, Hruska K: Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60:472-479.
16. Rajasree S, Umashankar PR, Lal AV, Sarma PS, Kartha CC: 1,25-Dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci 2002;70:1777-1788.
17. Rebsamen MC, Sun J, Norman AW, Liao JK: 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91:17-24.
18. McCarty MF: Secondary hyperparathyroidism promotes the acute phase response - A rationale for supplemental vitamin D in prevention of vascular events in the elderly. Med Hypotheses 2005;64:1022-1026.
19. Timms PM, Mannan N, Hitman GA, et al: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002;95:787-796.
20. Park CW, Oh YS, Shin YS, et al: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73-81.
21. McGonigle RJ, Fowler MB, Timmis AB, et al: Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron 1984;36:94-100.
22. Resnick LM, Muller FB, Laragh JH: Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 1986;105:649-654.
23. Burgess ED, Hawkins RG, Watanabe M: Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens 1990;3:903-905.
24. Li Y, Kong J, Wei M, et al: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-238.
25. Pfeifer M, Begerow B, Minne HW, et al: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001;86:1633-1637.
26. Xiang W, Kong J, Chen S, et al: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005;266:E125-E132.
27. Siren AL, Fratelli M, Brines M, et al: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-4049.
28. Cerami A: Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin Hematol 2001;38:33-39.
29. Fineberg N, Weinberg M: The influence of age on renal function and renin and aldosterone response to sodium-volume expansion and contraction in normotensive and mildly hypertensive humans. Am J Hypertens 1992;5:520-528.
30. McCullough PA, Sandberg KR, Yee J, Hudson MP: Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 2002;3:188-191.
31. Quinkler M, Zehnder D, Eardley KS, et al: Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005;112:1435-1443.
32. McCarty MF: Acid-base balance may influence risk for insulin resistance syndrome by modulating cortisol output. Med Hypotheses 2005;64:380-384.
33. Zoccali C, Mallamaci F, Tripepi G: Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003:S105-S110.
34. Zoccali C: Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif 2002;20:469-472.
35. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16(suppl 1):S83-S88.
36. Shoji T, Shinohara K, Kimoto E, et al: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-184.
37. Teng M, Wolf M, Lowrie E, et al: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
38. Levin A: The relationship of haemoglobin level and survival: direct or indirect effects? Nephrol Dial Transplant 2002;17:8-13.
39. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
40. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002;62:1784-1790.
41. Efrati S, Zaidenstein R, Dishy V, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002;40:1023-1029.